Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more
Cardiff Oncology Inc (CRDF) - Net Assets
Latest net assets as of December 2025: $45.39 Million USD
Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has net assets worth $45.39 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($61.88 Million) and total liabilities ($16.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $45.39 Million |
| % of Total Assets | 73.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | -67.68% |
| 10-Year Change | 129.6% |
| Growth Volatility | 489.29 |
Cardiff Oncology Inc - Net Assets Trend (2009–2025)
This chart illustrates how Cardiff Oncology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cardiff Oncology Inc (2009–2025)
The table below shows the annual net assets of Cardiff Oncology Inc from 2009 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $45.39 Million | -45.28% |
| 2024-12-31 | $82.95 Million | +18.94% |
| 2023-12-31 | $69.74 Million | -34.42% |
| 2022-12-31 | $106.34 Million | -24.27% |
| 2021-12-31 | $140.42 Million | +9.57% |
| 2020-12-31 | $128.16 Million | +1652.87% |
| 2019-12-31 | $7.31 Million | -27.50% |
| 2018-12-31 | $10.08 Million | +55.00% |
| 2017-12-31 | $6.51 Million | -67.09% |
| 2016-12-31 | $19.77 Million | -59.41% |
| 2015-12-31 | $48.70 Million | +483.32% |
| 2014-12-31 | $8.35 Million | -59.06% |
| 2013-12-31 | $20.39 Million | +840.16% |
| 2012-12-31 | $2.17 Million | +151.26% |
| 2011-12-31 | $-4.23 Million | +15.30% |
| 2010-12-31 | $-5.00 Million | -31.80% |
| 2009-12-31 | $-3.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cardiff Oncology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43003000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.02% |
| Other Comprehensive Income | $50.00K | 0.11% |
| Other Components | $475.36 Million | 1047.33% |
| Total Equity | $45.39 Million | 100.00% |
Cardiff Oncology Inc Competitors by Market Cap
The table below lists competitors of Cardiff Oncology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EASY HOLDINGS Co. Ltd
KQ:035810
|
$128.08 Million |
|
Greenpanel Industries Limited
NSE:GREENPANEL
|
$128.10 Million |
|
RocKontrol Technology Group Co Ltd
SHG:688051
|
$128.14 Million |
|
Prime US REIT
OTCGREY:KBSUF
|
$128.15 Million |
|
Young Optics Inc
TW:3504
|
$128.01 Million |
|
VESTUM AB AK
F:W0S
|
$128.00 Million |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
$127.97 Million |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
$127.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cardiff Oncology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 82,949,000 to 45,388,000, a change of -37,561,000 (-45.3%).
- Net loss of 45,876,000 reduced equity.
- Other comprehensive income increased equity by 16,000.
- Other factors increased equity by 8,299,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-45.88 Million | -101.08% |
| Other Comprehensive Income | $16.00K | +0.04% |
| Other Changes | $8.30 Million | +18.28% |
| Total Change | $- | -45.28% |
Book Value vs Market Value Analysis
This analysis compares Cardiff Oncology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.40x to 2.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $0.36 | $1.92 | x |
| 2005-12-31 | $9.55 | $1.92 | x |
| 2009-12-31 | $-54.14 | $1.92 | x |
| 2010-12-31 | $-50.24 | $1.92 | x |
| 2011-12-31 | $-31.37 | $1.92 | x |
| 2012-12-31 | $11.95 | $1.92 | x |
| 2013-12-31 | $86.48 | $1.92 | x |
| 2014-12-31 | $31.52 | $1.92 | x |
| 2015-12-31 | $132.56 | $1.92 | x |
| 2016-12-31 | $47.00 | $1.92 | x |
| 2017-12-31 | $13.51 | $1.92 | x |
| 2018-12-31 | $4.33 | $1.92 | x |
| 2019-12-31 | $1.22 | $1.92 | x |
| 2020-12-31 | $6.14 | $1.92 | x |
| 2021-12-31 | $3.60 | $1.92 | x |
| 2022-12-31 | $2.44 | $1.92 | x |
| 2023-12-31 | $1.56 | $1.92 | x |
| 2024-12-31 | $1.74 | $1.92 | x |
| 2025-12-31 | $0.68 | $1.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cardiff Oncology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -101.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7736.26%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.36x
- Recent ROE (-101.08%) is above the historical average (-118.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -103.67% | 0.00% | 0.00x | -0.21x | $-5.89 Million |
| 2005 | -79.07% | 0.00% | 0.00x | -0.56x | $-8.84 Million |
| 2009 | 0.00% | -381.54% | 0.86x | 0.00x | $-2.10 Million |
| 2010 | 0.00% | -2051.13% | 0.52x | 0.00x | $-4.95 Million |
| 2011 | 0.00% | -868.94% | 0.25x | 0.00x | $-1.82 Million |
| 2012 | -533.24% | -2570.22% | 0.04x | 5.38x | $-11.78 Million |
| 2013 | -57.92% | -4555.88% | 0.01x | 1.33x | $-13.85 Million |
| 2014 | -171.58% | -5116.07% | 0.01x | 3.46x | $-15.16 Million |
| 2015 | -56.41% | -8776.68% | 0.00x | 1.47x | $-32.34 Million |
| 2016 | -198.32% | -10289.76% | 0.01x | 2.22x | $-41.18 Million |
| 2017 | -382.83% | -4932.08% | 0.04x | 1.89x | $-25.56 Million |
| 2018 | -163.24% | -4354.76% | 0.03x | 1.41x | $-17.47 Million |
| 2019 | -224.50% | -6709.74% | 0.02x | 1.79x | $-17.15 Million |
| 2020 | -15.06% | -5275.14% | 0.00x | 1.05x | $-32.12 Million |
| 2021 | -20.15% | -7880.50% | 0.00x | 1.06x | $-42.33 Million |
| 2022 | -36.40% | -10026.94% | 0.00x | 1.09x | $-49.34 Million |
| 2023 | -59.42% | -8492.01% | 0.01x | 1.17x | $-48.41 Million |
| 2024 | -54.77% | -6651.68% | 0.01x | 1.17x | $-53.73 Million |
| 2025 | -101.08% | -7736.26% | 0.01x | 1.36x | $-50.41 Million |
Industry Comparison
This section compares Cardiff Oncology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cardiff Oncology Inc (CRDF) | $45.39 Million | -103.67% | 0.36x | $128.08 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |